Wyeth increases stake in Wyeth KK
USA-based Wyeth says it has purchased an additional 10% stake in Wyeth KK, the joint venture it co-owns with Japan's Takeda, bringing Wyeth's holding in the firm to 80%. The move is in line with Wyeth's decision to buy WKK outright, that it announced last year (Marketletter April 11, 2005).
Wyeth KK was founded in 1953, as Lederle, in a joint venture between Takeda and US group Cyanamid, which was subsequently acquired by Wyeth. Key Wyeth KK products include the rheumatoid arthritis drug Enbrel (etanercept) and Mylotarg (gemtuzumab ozogamicin), a humanized anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia, both of which were launched in Japan in 2005.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze